Cure8 news brief
TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming alternatives, but business articles rarely include clinical detail needed for care decisions.
Adult patients with ulcerative colitis or Crohn's disease, people on or considering biologic therapies, gastroenterologists, and researchers following IBD drug development.
The news item reports that J&J presented "promising data" for TREMFYA in both UC and Crohn's at DDW 2025. The piece focuses on the business impact (share performance, earnings, and market positioning) rather than clinical specifics. No patient-level results, endpoints, or safety information are given in the article text provided.
If you want clinical details, look for the original DDW abstract, a peer-reviewed conference poster, or coverage from clinical/medical news sources; those will report study design, endpoints, and results needed to assess benefit and risks. This article does not imply any change to clinical care.
Discuss any treatment questions with your gastroenterology team.
This is a finance/market-focused article summarizing J&J's DDW presentation and its potential positive impact on the company's immunology portfolio and stock sentiment. It does not report clinical results or study methodology. For clinical interpretation, consult the original DDW abstract or medical coverage.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
